WJPMR, 2026, 12(6), 381-386

Review Article

Impact Factor: 7.533

WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.wjpmr.com

ISSN (O): 2455-3301

ISSN (P): 3051-2557

Coden USA: WJPMBB

ARTIFICIAL-INTELLIGENCE: REVOLUTIONIZING DRUG DISCOVERY, HEALTHCARE, AND THE PHARMACEUTICAL LANDSCAPE

Prachi D. Patil*

India.

***Corresponding Author: Prachi D. Patil**

India.

DOI: https://doi.org/10.5281/zenodo.20525540

How to cite this Article: Prachi D. Patil* (2026). Artificial-Intelligence: Revolutionizing Drug Discovery, Healthcare, And The Pharmaceutical Landscape. World Journal of Pharmaceutical and Medical Research, 12(6), 381–386.

Article Received on 04/05/2026 **Article Revised on 25/05/2026** **Article Published on 01/06/2026**

ABSTRACT

The traditional drug discovery process is inherently characterised by complexity, high costs, lengthy timelines, and a low success rate. Artificial intelligence (AI) and machine learning (ML), a subset of AI, offer transformative potential to address these persistent challenges. By leveraging techniques such as deep learning (DL) and Natural Language Processing (NLP), AI systems can analyse vast datasets, accelerate timelines, reduce costs, and significantly increase the efficiency and success rates of pharmaceutical research. AI applications span the entire drug discovery pipeline, from identifying molecular targets and screening compounds to predicting toxicity, optimising formulations, and enhancing clinical trials. While AI holds the promise of delivering safer, more effective, and more accessible medicines, its integration faces critical hurdles related to data quality, algorithmic bias, model interpretability ("black box" issues), and the development of adequate regulatory frameworks.

KEYWORDS: Artificial Intelligence, Machine Learning, Deep Learning, Drug Discovery, Target Identification, Drug Repurposing, Personalized Medicine.

INTRODUCTION

Artificial intelligence (AI) encompasses a broad field dedicated to creating machines capable of performing tasks traditionally requiring human intelligence, such as reasoning, learning, and decision-making. In the context of drug discovery, AI relies heavily on Machine Learning (ML), a subfield focused on enabling systems to learn from data to predict outcomes and generate outputs without explicit programming.[1] Deep Learning (DL) is a highly sophisticated subset of ML that uses artificial neural networks (ANNs) with multiple layers to analyse complex, unstructured data and model intricate relationships. The complexity of the traditional drug discovery process, which often spans over a decade and exceeds 2 billion, necessitates more efficient methods.[2] Critically, this traditional process suffers from a low success rate, with only about 10% of drugs entering clinical trials ultimately achieving regulatory approval. AI, ML, and DL offer a promising path towards increasing efficiency and success rates across the pharmaceutical pipeline. For instance, AI applications can potentially reduce the average time required for the entire process from 10–15 years to 7–9 years.[3]

AI in Drug Discovery & Healthcare

AI and ML are fundamentally reshaping pharmaceutical research and development, from target selection to clinical outcomes.[4]

In Drug Discovery

The integration of AI spans the entire drug discovery process, which typically involves target identification, hit generation, lead identification and optimisation, and preclinical testing.

Target Identification and Validation: AI significantly accelerates the identification of relevant biological targets by analysing vast omics datasets, including genomics, proteomics, and transcriptomics.[5] AI/ML techniques are essential for processing complex, high-dimensional omics data and identifying potential disease-associated targets.[6]

Lead Discovery and Design: AI facilitates both virtual screening (VS) and *de novo* drug design. VS leverages ML algorithms to rapidly sift through vast compound libraries, prioritising candidates with the highest therapeutic potential against specific targets6. For *de* *novo* design, generative AI models like Generative Adversarial Networks (GANs) and Graph Neural Networks (GNNs) generate novel, optimised molecular structures that adhere to desired properties and pharmacological profiles.[7]

Lead Optimization and ADMET Prediction: Once a lead compound is identified, AI accelerates the refinement of its potency, selectivity, and pharmacokinetic properties. AI algorithms are widely used for predicting Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) parameters, which is crucial for safety and increasing the success rate of clinical trials. Predictive models such as Deep Tox enable the identification of potentially toxic compounds early on, reducing the time and cost associated with preclinical testing.[8]

In Healthcare and Personalized Medicine

AI applications in healthcare include medical image analysis, personalized treatment planning, disease diagnosis, and patient monitoring.[9]

Personalized Treatment: AI models forecast disease outcomes and optimize treatment strategies based on unique patient characteristics, including genetic profiles, medical history, and lifestyle choices. Platforms like CURATE.AI, for example, dynamically tailor treatment intervention intensity to individual patient responses using time-specific data points.[10]

Clinical Trials Enhancement: AI is used to streamline clinical trials by predicting outcomes, assisting with patient-trial matching and recruitment, and continuously monitoring adherence, thereby reducing costs and accelerating time-to-market.[11]



Fig.no.1: AI In Drug Discovery & Healthcare.

AI in Data Analysis & Big Data

The feasibility of AI in drug discovery relies on the effective processing of vast and complex data structures, moving the pharmaceutical sector into the "big data" era.[12]

Data Resources and Complexity

Data resources used by AI algorithms are voluminous, diverse, and rapidly growing, including public databases like ChEMBL, PubChem, Drug Bank, and DGIdb, as well as proprietary R&D data. Crucially, vast amounts of heterogeneous data are generated through *multi-omics* studies (genomics, proteomics, metabolomics, etc.), posing major challenges for analysis due to variability and lack of standardization.[12] AI excels in processing this complex, high- dimensional data, a task that traditional analytical methods struggle with.[13]



Fig.no.2: AI In Pharmaceutical Data Analysis.

AI Techniques for Data Processing

Handling Unstructured Data: Natural Language Processing (NLP) techniques are essential for deriving meaningful insights from unstructured text data, such as scientific literature, patents, clinical reports, and Electronic Health Records (EHRs). NLP models are used to identify drug names, targets, and extract complex biological interactions, often feeding this structured information into predictive models.[14]



Fig.no.3: AI Techniques For DATA Processing In Pharmaceutical Industry.

Integrating Multi-Omics Data: AI/ML algorithms are used for *multi-omics* integration, linking genomic, transcriptomic, and proteomic data to disease mechanisms, accelerating target identification, and enabling personalized therapeutic options.[15]

Feature Extraction and Representation: For computational processing, molecules must be converted into a computer-readable format. AI techniques automate the process of translating chemical structures into molecular descriptors, fingerprints (e.g., ECFP), or graph representations, ensuring that intrinsic physicochemical properties are preserved for accurate modeling and prediction.[16]

Ethical and Regulatory Challenges of AI

The responsible integration of AI into pharmaceutical research and healthcare requires proactively addressing significant ethical and regulatory challenges.[17]

Ethical Concerns

Data Quality and Bias: AI models are highly dependent on the quality and diversity of the data they are trained on. Biases embedded in training datasets, potentially reflecting demographic inequities or experimental biases, can lead to skewed predictions and compromise the generalizability of the models, potentially affecting underrepresented populations.[18]

Transparency and Interpretability: A key hurdle is the "black box" nature of many sophisticated AI models, especially deep learning networks, making it difficult for researchers, clinicians, and regulators to understand *how* predictions are reached. This opacity undermines trust and rigorous validation.[1]

Privacy and Accountability: Handling vast amounts of sensitive patient data raises serious concerns regarding privacy and accountability.[2] Adherence to strict regulations such as the General Data Protection Regulation (GDPR) in the European Union and the Health Insurance Portability and Accountability Act (HIPAA) in the U.S. is essential to safeguard protected health information.[3]



Fig.no.4: Ethical & Regulatory Challenges Of AI In Pharmaceutical Industry.

Regulatory Landscape

Regulatory bodies, including the FDA (Food and Drug Administration) and EMA (European Medicines Agency), are actively developing safety parameters and guidelines to govern AI technologies in drug development and validation.[4] The current regulatory environment is still evolving to establish clear validation metrics and pathways for demonstrating the reliability and robustness of AI-driven evidence.[5] The absence of standardized protocols for AI-generated drug candidates often complicates regulatory approva.[16]

AI Algorithms and Techniques

AI in drug discovery leverages a hierarchy of methods, with machine learning (ML) and deep learning (DL) forming the core.[7]

Machine Learning Paradigms

Supervised Learning: Algorithms are trained on labeled data to perform classification (e.g., determining if a compound is active/inactive using Support Vector Machines [SVMs] or Random Forests [RF]) or regression (e.g., predicting property values using Multiple Linear Regression [MLR] or Decision Trees [DT]).[8]

Unsupervised Learning: Algorithms detect hidden patterns in unlabeled data, frequently used for clustering compounds or dimensionality reduction (e.g., k-means clustering, Principal Component Analysis [PCA]) in chemical space exploration.[9]

Reinforcement Learning (RL): An agent learns optimal actions through trial and error within a defined environment, maximizing a reward signal; this is used for complex tasks like molecular design optimization.[10]

Deep Learning Architectures

DL uses multilayered Artificial Neural Networks (ANNs) to learn complex data representations automatically.

Convolutional Neural Networks (CNNs): Excel at processing structured data, such as 2D/3D images of molecular structures or high-content screening data.

Recurrent Neural Networks (RNNs): Specialized for sequential data, such as chemical sequences (SMILES strings) or protein sequences.[11]

Graph Neural Networks (GNNs): Highly effective for modeling molecules as graphs (atoms as nodes, bonds as edges), capturing intricate relational and structural information critical for drug-target interaction prediction and property modeling.

Generative Adversarial Networks (GANs): A pair of competing networks used primarily to generate novel molecular structures (*de novo* drug design).[12]

Other Techniques

Natural Language Processing (NLP): Enables computers to process and understand human language, vital for text mining scientific literature and EHRs.

Transformer Models: Revolutionized NLP (e.g., BERT, GPT), often adapted to sequence- based tasks in computational biology and target identification (e.g., Mol-BERT, ESM-2).[13]

AI in Automation and Robotics

AI is deeply integrated with automation and robotics to accelerate experimental workflows, manufacturing, and supply chain logistics.[14]

Automated R&D and Synthesis: AI guides robotic systems to streamline laboratory processes, such as sample analysis, sorting, and preparation, effectively minimizing human error and enhancing data accuracy. The "Chem puter" exemplifies AI-driven robotics used for the automated synthesis of drug molecules.[15]

Manufacturing and Quality Control (QC): In pharmaceutical manufacturing, AI optimizes processes, ensures stringent QC, and improves production efficiency. AI systems enable real- time visual inspection and monitoring, utilizing computer vision to detect product defects and ensure compliance.[16]

Intelligent Process Automation and Digital Twins: Intelligent Process Automation integrates AI tools like IoT sensors and computer vision to streamline complex supply chain and manufacturing processes, boosting accuracy and throughput. Digital Twin Technology creates virtual replicas of manufacturing lines to simulate, monitor, and optimize processes dynamically without physical disruption.[17]

Predictive Maintenance: AI-driven predictive maintenance utilizes sensor data analysis to forecast equipment failures, allowing for proactive maintenance scheduling, which significantly reduces unexpected downtime and operational costs.[18]



Fig.no. 5: AI In Automation & Robotics In Pharmaceutical Industry.

AI in Education and Training

The successful adoption of AI in the pharmaceutical industry depends on developing a highly skilled workforce proficient in both life sciences and computational methods. A key challenge is the existing skills gap in the development, deployment, and interpretation of complex AI/ML models. Addressing this gap requires substantial investment in comprehensive training and education programs.[4] The objective is to foster interdisciplinary collaboration, ensuring that AI specialists understand pharmaceutical domain knowledge and vice versa, which is crucial for successfully integrating AI into routine drug discovery practice.[5]

Future Trends

The future of AI in the pharmaceutical sector is defined by several key trends aimed at increasing reliability, interpretability, and scope.

Explainable AI (XAI): There is a significant need for research into XAI methods to translate the outputs of "black box" models into transparent, biologically or chemically meaningful explanations, building trust among scientists and policymakers.[6]

Advanced Data Integration and Sharing: Future research must emphasize multimodal data integration, combining diverse data types—such as omics data, clinical end points, and *in vivo* results—to accurately reflect complex biological and physiological contexts.[2] Furthermore, promoting data standardization and employing secure sharing mechanisms like Federated Learning are crucial for overcoming data silos and mitigating bias.[8]

Next-Generation Modeling: Continuous advancements are expected in novel modeling techniques, including integrating large language models (LLMs) for complex knowledge extraction and design tasks, which could optimize clinical trial design and target identification.[7] Advanced molecular docking methodologies, particularly those leveraging generative models like Diff Dock, are expected to revolutionize lead discovery.[9]

Translational Validation: Future studies must prioritize moving beyond *in silico* predictions toward comprehensive validation using real-world clinical and translational parameters to ensure the robustness and applicability of AI models for diverse patient populations.[18]

CONCLUSION

AI and ML have fundamentally transformed the pharmaceutical landscape, significantly accelerating the processes of drug discovery and development. AI applications, including enhanced target and lead identification, molecular optimization, and expedited safety assessments, offer unparalleled advantages in efficiency, cost reduction, and shortening development timelines. However, widespread adoption is hindered by persistent challenges, notably concerning ensuring robust data quality, resolving the interpretability issues associated with "black box" models, and establishing transparent, ethically sound regulatory frameworks. To fully realize AI's transformative potential, continuous scientific innovation, mandatory implementation of XAI, and collaborative engagement among academic, industry, and regulatory bodies are essential to ensure the creation of safe, effective, and accessible medicines globally.

REFERENCES

1. Herráiz-Gil S, Nygren-Jiménez E, Acosta-Alonso DN, León C, Guerrero-Aspizua S. Artificial Intelligence-Based Methods for Drug Repurposing and Development in Cancer. Appl Sci, 2025 Mar 5; 15(5): 2798.
2. Huanbutta K, Burapapadh K, Kraisit P, Sriamornsak P, Ganokratanaa T, Suwanpitak K, et al. Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. Eur J Pharm Sci, 2024 Dec; 203: 106938.
3. Visan AI, Negut I. Integrating Artificial Intelligence for Drug Discovery in the Context of Revolutionizing Drug Delivery. Life, 2024 Feb 7; 14(2): 233.
4. Dhudum R, Ganeshpurkar A, Pawar A. Revolutionizing Drug Discovery: A Comprehensive Review of AI Applications. Drugs Drug Candidates, 2024 Feb 13; 3(1): 148–71.
5. Yadav S, Singh A, Singhal R, Yadav JP. Revolutionizing drug discovery: The impact of artificial intelligence on advancements in pharmacology and the pharmaceutical industry. Intell Pharm, 2024 June; 2(3): 367–80.
6. Fu C, Chen Q. The future of pharmaceuticals: Artificial intelligence in drug discovery and development. J Pharm Anal, 2025 Aug; 15(8): 101248.
7. Faculty of Engineering Kampala International University Uganda, Kwemoi KC. The Role of Artificial Intelligence in Accelerating Drug Discovery Innovations. Res Invent J Sci Exp Sci, 2025 Mar 3; 5(1): 9–13.
8. Wu Y, Ma L, Li X, Yang J, Rao X, Hu Y, et al. The role of artificial intelligence in drug screening, drug design, and clinical trials. Front Pharmacol, 2024 Nov 29; 15: 1459954.
9. Boomisha S. D.JCH. AI in Drug Discovery, 2025 Feb 21 [cited 2025 Dec 15]; Available from: https://zenodo.org/doi/10.5281/zenodo.14907864
10. Duan FL, Duan CB, Xu HL, Zhao XY, Sukhbaatar O, Gao J, et al. AI-driven drug discovery from natural products. Adv Agrochem, 2024 Sept; 3(3): 185–7.
11. Ferreira FJN, Carneiro AS. AI-Driven Drug Discovery: A Comprehensive Review. ACS Omega, 2025 June 17; 10(23): 23889–903.
12. Nilesh Savale. Artificial Inteligence Used in Drug Discovery, 2025 Mar 3 [cited 2025 Dec 15]; Available from: https://zenodo.org/doi/10.5281/zenodo.14961715
13. Serrano DR, Luciano FC, Anaya BJ, Ongoren B, Kara A, Molina G, et al. Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine. Pharmaceutics, 2024 Oct 14; 16(10): 1328.
14. Bhat AR, Ahmed S. Artificial intelligence (AI) in drug design and discovery: A comprehensive review. Silico Res Biomed, 2025; 1: 100049.
15. Chen W, Liu X, Zhang S, Chen S. Artificial intelligence for drug discovery: Resources, methods, and applications. Mol Ther - Nucleic Acids, 2023 Mar; 31: 691–702.
16. Niazi SK, Mariam Z. Artificial intelligence in drug development: reshaping the therapeutic landscape. Ther Adv Drug Saf, 2025 Jan; 16: 20420986251321704.
17. Krosuri P, Pravallika G, Paravathi G, Sumanasri J, Akhila C, SriNikitha S. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY. (1001).
18. Kant S, Deepika, Roy S. Artificial intelligence in drug discovery and development: transforming challenges into opportunities. Discov Pharm Sci, 2025 June 2; 1(1): 7.